Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. is set to host a virtual event on May 29, 2024, discussing the clinical development of EP-104GI for treating Eosinophilic Esophagitis (EoE). The event will feature insights from Dr. Evan S. Dellon and company management, focusing on the RESOLVE clinical trial and future plans, leveraging their proprietary DiffuSphere™ technology aimed at improving EoE treatment outcomes.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
